Folate-engineered chitosan nanoparticles: next-generation anticancer nanocarriers
Molecular Cancer,
Год журнала:
2024,
Номер
23(1)
Опубликована: Окт. 31, 2024
Chitosan
nanoparticles
(NPs)
are
well-recognized
as
promising
vehicles
for
delivering
anticancer
drugs
due
to
their
distinctive
characteristics.
They
have
the
potential
enclose
hydrophobic
molecules,
thereby
enhancing
solubilities,
permeabilities,
and
bioavailabilities;
without
use
of
surfactant,
i.e.,
through
surfactant-free
solubilization.
This
allows
higher
drug
concentrations
at
tumor
sites,
prevents
excessive
toxicity
imparted
by
surfactants,
could
circumvent
resistance.
Moreover,
biomedical
engineers
formulation
scientists
can
also
fabricate
chitosan
NPs
slowly
release
agents.
keeps
site
longer,
makes
therapy
more
effective,
lowers
frequency
dosing.
Notably,
some
types
cancer
cells
(fallopian
tube,
epithelial
tumors
ovary,
primary
peritoneum;
lung,
kidney,
ependymal
brain,
uterus,
breast,
colon,
malignant
pleural
mesothelioma)
overexpression
folate
receptors
(FRs)
on
outer
surface,
which
lets
folate-drug
conjugate–incorporated
target
kill
them
effectively.
Strikingly,
there
is
evidence
suggesting
that
excessively
produced
FR&αgr
(isoforms
FR)
stays
consistent
throughout
treatment
in
ovarian
endometrial
cancer,
indicating
resistance
conventional
treatment;
this
regard,
folate-anchored
overcome
it
improve
therapeutic
outcomes.
Interestingly,
overly
expressed
FRs
present
only
certain
types,
a
biomarker
predicting
effectiveness
FR-targeted
therapy.
On
other
hand,
folate-modified
enhance
oral
absorption
medicines,
especially
drugs,
pave
way
effective
long-term
low-dose
metronomic
scheduling
poorly
soluble
permeable
drugs.
In
review,
we
talked
briefly
about
techniques
used
create,
characterize,
tailor
chitosan-based
NPs;
delved
deeper
into
applications
folate-engineered
treating
various
types.
Schematic
illustration
ligand-drug
incorporated
its
advantage
cancer.
Figure
created
with
BioRender.Com.
Язык: Английский
Harnessing phytoconstituents in ethosomes: A new frontier in skin disorder management
International Journal of Pharmaceutics,
Год журнала:
2025,
Номер
unknown, С. 125273 - 125273
Опубликована: Янв. 1, 2025
Язык: Английский
Current Status of Gout Arthritis: Current Approaches to Gout Arthritis Treatment: Nanoparticles Delivery Systems Approach
Pharmaceutics,
Год журнала:
2025,
Номер
17(1), С. 102 - 102
Опубликована: Янв. 14, 2025
The
deposition
of
monosodium
urate
(MSU)
crystals
within
joint
spaces
produces
a
painful
inflammatory
condition
known
as
gout,
specific
form
arthritis.
calls
for
combined
curative
and
preventive
management
model.
A
new
development
in
the
approach
to
gout
is
that
NLRP3-targeted
biologic
agents,
such
monoclonal
therapies,
provide
more
accurate
treatment
by
blocking
pro-inflammatory
cytokines.
Nanoparticle
drug
delivery
enhances
biological
availability
targets,
which
may
increase
therapeutic
efficacy
decrease
general
toxicity.
again
cannot
be
ignored,
mainly
keeping
up
certain
modifications
diet
weight,
along
with
pharmacological
therapies
reduce
uric
acid
(UA)
levels
frequency
acute
attacks.
advancement
genetic
profiling
patients
biomarker
discoveries
drives
trend
towards
building
individualized
medicine
care,
quickly
gaining
ground
most
effective
method
delivering
treatments
individual
patients,
moving
away
from
one-size-fits-all
treatments.
following
paper
aims
an
updated
account
focus
on
recent
developments,
order
enhance
these
approaches,
quality
life
standard
treatment.
Язык: Английский
Eucalyptol Attenuates Indomethacin-Induced Gastric Ulcers in Rats by Modulating the ICAM-1, eNOS and COX/LOX Pathways: Insights from In Silico, In Vitro and In Vivo Approaches
Food and Chemical Toxicology,
Год журнала:
2025,
Номер
unknown, С. 115319 - 115319
Опубликована: Фев. 1, 2025
Язык: Английский
Nano-Phytoconstituents: Recent Advances, Regulatory Insights, Challenges, and Future Horizons
Journal of Drug Delivery Science and Technology,
Год журнала:
2025,
Номер
unknown, С. 106908 - 106908
Опубликована: Апрель 1, 2025
Язык: Английский
Unlocking the future of osteoarthritis: Material engineering and drug delivery confluence for advanced therapeutic approaches
Journal of Drug Delivery Science and Technology,
Год журнала:
2024,
Номер
101, С. 106264 - 106264
Опубликована: Окт. 9, 2024
Язык: Английский
Edge advances in nanodrug therapies for osteoarthritis treatment
Frontiers in Pharmacology,
Год журнала:
2024,
Номер
15
Опубликована: Окт. 30, 2024
As
global
population
and
lifestyles
change,
osteoarthritis
(OA)
is
becoming
a
major
healthcare
challenge
world.
OA,
chronic
condition
characterized
by
inflammatory
degeneration,
often
present
with
joint
pain
can
lead
to
irreversible
disability.
While
there
currently
no
cure
for
it
commonly
managed
using
nonsteroidal
anti-inflammatory
drugs
(NSAIDs),
glucocorticoids,
glucosamine.
Although
these
treatments
alleviate
symptoms,
difficult
effectively
deliver
sustain
therapeutic
agents
within
joints.
The
emergence
of
nanotechnology,
particularly
in
form
smart
nanomedicine,
has
introduced
innovative
approaches
OA
treatment.
Nanotherapeutic
strategies
offer
promising
advantages,
including
more
precise
targeting
affected
areas,
prolonged
effects,
enhanced
bioavailability,
reduced
systemic
toxicity
compared
traditional
treatments.
nanoparticles
show
potential
as
viable
delivery
system
therapies
based
on
encouraging
lab-based
clinical
trials
results,
remails
considerable
gap
between
current
research
application.
This
review
highlights
recent
advances
nanotherapy
explore
future
pathways
refine
optimize
strategies.
Язык: Английский